ﺑﺮرﺳﯽ ﺑﯿﺎن ژن BAX در مخچه موش‌های صحرایی کلستاتیک تجربی، ﻣﺘﻌﺎﻗﺐ اﺛﺮ داروی ﻧﻮرواﯾﺪ
محورهای موضوعی : زیست شناسی سلولی تکوینی گیاهی و جانوری ، تکوین و تمایز ، زیست شناسی میکروارگانیسم
افسانه کریمی آنچه
1
(دانشجو)
مهرداد هاشمی
2
(گروه ژنتیک ،دانشکده علوم نوین ،دانشگاه آزاد اسلامی واحد علوم پزشکی تهران ، تهران ،ایران)
محمد ناصحی
3
(گروه فیزیولوژی جانوری ،گروه زیست شناسی،دانشکده علوم نوین ،دانشگاه آزاد اسلامی واحد علوم پزشکی تهران ،تهران ،ایران)
کلید واژه: واژگان کلیدی: ", کلستاز", , ", ژنBax", , ", نوراید", , ", مخچه", , ", آپوپتوز", ,
چکیده مقاله :
چکیده: سابقه و هدف: کلستاز ازجمله بیماری‌های کبدی است که ازلحاظ عملکردی با کاهش یا قطع جریان صفرا همراه می‌باشد و باعث تجمع اسیدهای صفراوی در خون می‌شود، در صورت عدم درمان، کلستاز سبب آسیب به اندام‌های مختلف می‌گردد. در این تحقیق تأثیر کلستاز بر بیان ژن Bax که درروند مرگ برنامه‌ریزی‌شده‌ی سلول (آپوپتوز) مؤثراست، بررسی شد. روش بررسی: تعداد ۱۶ سر رت نر به ۴ گروه تقسیم شدند: گروه کنترل یا شاهد، گروه BDL: در این گروه مجرای صفراوی به شکل مصنوعی بسته شد، گروه BDL نوراید: در این گروه علاوه بربستن مجرای صفراوی، رت ها با داروی نوراید نیز تیمار شدند، گروه شم نوراید: در این گروه علاوه بر اینکه رت ها تحت استرس جراحی قرار گرفتند داروی نوراید نیز دریافت نمودند. سپس مخچه‌ی رت ها خارج شد. پس از استخراج RNA و سنتز cDNA، بیان ژن‌ها با فن‌آوری Real Time PCR موردبررسی قرار گرفت. یافته‌ها: BDL باعث افزایش بیان ژن Bax و استفاده از داروی نوراید باعث کاهش بیان ژن Bax در ناحیه‌ی مخچه رت ها شد. نتیجه‌گیری: تغییرات ایجادشده توسط کلستاز در جهت افزایش آپوپتوز در ناحیه‌ی مخچه‌ی رت ها می‌باشد و استفاده از داروی نوراید می‌تواند باعث کاهش آپوپتوز در مخچه‌ی رت ها شود.
Background: Including liver diseases is cholestasis which is a consequence of disordered bile secretion causes an accumulation of poisonous bile in the body. If untreated, Cholestasis is causing damage to various organs. In this research was planned to investigate the effects of cholestasis and neuroaid (a drug which protects and repairs neurons) on the expression of Bax gene, in cerebellum of rat brain. Bax has role in apoptosis. Methods: A total number of 16 rats were divided into four groups as follows: Control group. BDL group, the rats which were just operated for bile duct ligation. BDL-neuroaid group, the rats which received both operation and neuroaid. Sham-neuroaid group, the rats which were not operated, but received the operation stress and neuroaid. Following the treatments, the rats were killed and their cerebellum were removed from their brain. RNA was extracted from the cerebellum cells, cDNA was synthesized, and Real time PCR was performed to measure the gene expression. Results: According To the results, cholestasis causes increase in the expression of Bax gene; Neuroaid causes reduces in the expression Bax gene. Conclusion: Cholestasis changes is benefit to increase internal apoptosis pathway, however, neuroaid can approximately reduce this effect as well through making reduces Bax gene and as a result reduction of apoptosis, in cerebellum of rat brain
[1] Apps, R., and S. Lee.1999 .Gating of transmission in climbing fibre paths to cerebellar cortical C1 and C3 zones in the rostral paramedian lobule during locomotion in the cat. J Physiol 516 (Pt 3): 875-83.
[2] Arduini, A., et al. 2012. Mitochondrial dysfunction in cholestatic liver diseases. Front Biosci (Elite Ed) 4: 2233-52.
[3] Baron, V., et al. 2000. Nitric oxide and inducible nitric oxide synthase expression are downregulated in acute cholestasis in the rat accompanied by liver ischemia. Comp Biochem Physiol C Toxicol Pharmacol 127 (3): 243-9.
[4] Behroozaghdam, M., et al. 2015. Expression of bax and bcl2 Genes in MDMA-induced Hepatotoxicity on Rat Liver Using Quantitative Real-Time PCR Method through Triggering Programmed Cell Death. Iran Red Crescent Med J 17 (11): e24609.
[5] Boehm, I. 2006.Apoptosis in physiological and pathological skin: implications for therapy. Curr Mol Med 6(4):375-94.
[6] Chan, H. Y., and L. W. Stanton. 2016. A pharmacogenomic profile of human neural progenitors undergoing differentiation in the presence of the traditional Chinese medicine NeuroAiD. Pharmacogenomics J 16(5):461-71.
[7] Chen, C. L., et al. 2013.The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES). Cerebrovasc Dis 35 Suppl 1: 23-9.
[8] Coco, M., and V. Perciavalle. 2015.Where did the motor function of the cerebellum come from? Cerebellum Ataxias 2: 10.
[9] Collett, J. A., et al. 2015. Kidney-Specific Reduction of Oxidative Phosphorylation Genes Derived from Spontaneously Hypertensive Rat. PLoS One 10 (8): e0136441.
[10] Deroee, A. F., et al. 2010. Cholestasis induced nephrotoxicity: the role of endogenous opioids. Life Sci 86 (13-14): 488-92.
[11] Emel'ianchik, S. V., and S. M. Zimatkin. 2013. [Structural and histochemical changes in the rat cerebellum Purkinje cells after cholestasis]. Morfologiia 143 (2): 19-23.
[12] Esfandiary, E., et al. 2014. Novel effects of Rosa damascena extract on memory and neurogenesis in a rat model of Alzheimer's disease. J Neurosci Res 92(4): 517-30.
[13] Feng, R., et al. 2001. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron 32(5):911-26.
[14] Fonseca, L. F., et al. 2015. Expression of genes related to mitochondrial function in Nellore cattle divergently ranked on residual feed intake. Mol Biol Rep 42(2): 559-65.
[15] Forton, D. M., S. D. Taylor-Robinson, and H. C. Thomas. 2002. Reduced quality of life in hepatitis C--is it all in the head? J Hepatol 36(3):435-8.
[16] Garmabi, B., et al. 2016. Effect of circadian rhythm disturbance on morphine preference and addiction in male rats: Involvement of period genes and dopamine D1 receptor. Neuroscience 322: 104-14.
[17] Ghonem, N. S., D. N. Assis, and J. L. Boyer. 2015. Fibrates and cholestasis. Hepatology 62 (2): 635-43.
[18] Guicciardi, M. E., and G. J. Gores. 2002. Bile acid-mediated hepatocyte apoptosis and cholestatic liver disease. Dig Liver Dis 34 (6): 387-92.
[19] Haddad, J. J. 2004. Redox and oxidant-mediated regulation of apoptosis signaling pathways: immuno-pharmaco-redox conception of oxidative siege versus cell death commitment. Int Immunopharmacol 4 (4): 475-93.
[20] Hayashi, H., et al. 2016. Successful treatment with 4-phenylbutyrate in a patient with benign recurrent intrahepatic cholestasis type 2 refractory to biliary drainage and bilirubin absorption. Hepatol Res 46 (2): 192-200.
[21] Heurteaux, C., et al. 2010. Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology 58 (7): 987-1001.
[22] Heurteaux, C., et al. 2013. NeuroAiD: properties for neuroprotection and neurorepair. Cerebrovasc Dis 35 Suppl 1: 1-7.
[23] Holt, S. H., et al. 2016. Activation of apoptosis in NAF-1-deficient human epithelial breast cancer cells. J Cell Sci 129 (1): 155-65.
[24] Holt, S., et al. 1999. Acute cholestasis-induced renal failure: effects of antioxidants and ligands for the thromboxane A2 receptor. Kidney Int 55 (1): 271-7.
[25] Hosseini, N., et al. 2014a. Effects of cholestasis on learning and locomotor activity in bile duct ligated rats. Malays J Med Sci 21 (1): 19-28.
[26] Hosseini, N., et al. 2014b. Cholestasis progression effects on long-term memory in bile duct ligation rats. Adv Biomed Res 3: 215.
[27] Hosseini, N., et al. 2013. Effects of CA1 glutamatergic systems upon memory impairments in cholestatic rats. Behav Brain Res 256: 636-45.
[28] Jacquemin, E. 2012. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol 36 Suppl 1: S26-35.
[29] Kikalishvili, L. A., et al. 2009. Morphological changes in brain and heart after the temporary liver exclusion from the bloodstream during the cholestasis]. Georgian Med News (167):77-81.
[30] Le Sueur-Maluf, L., et al. 2015. Behavioral alterations and Fos protein immunoreactivity in brain regions of bile duct-ligated cirrhotic rats. An Acad Bras Cienc 87 (1): 331-493.
[31] Ljubuncic, P., I. Yousef, and A. Bomzon. 2004. Cholemic transgenic mice: a novel animal model to investigate the effects of bile acids. J Pharmacol Toxicol Methods 50 (3): 231-5.
[32] Mani, A. R., et al. 2002. Dual nitric oxide mechanisms of cholestasis-induced bradycardia in the rat. Clin Exp Pharmacol Physiol 29 (10): 905-8.
[33] Monfort, P., et al. 2002. Effects of hyperammonemia and liver failure on glutamatergic neurotransmission. Metab Brain Dis (17( 4: 50-237.
[34] Nguyen, K. D., V. Sundaram, and W. S. Ayoub. 2014. Atypical causes of cholestasis. World J Gastroenterol 20 (28): 9418-26.
[35] Paumgartner, G. 2006. Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets. World J Gastroenterol 12 (28): 4445-51.
[36] Quintard, H., et al. 2011. MLC901, a traditional Chinese medicine protects the brain against global ischemia. Neuropharmacology 61 (4): 622-31.
[37] Quintard, H., et al. 2014. MLC901, a Traditional Chinese Medicine induces neuroprotective and neuroregenerative benefits after traumatic brain injury in rats. Neuroscience 277: 72-86.
[38] Radahmadi, M., et al. 2015. Preventive and therapeutic effect of treadmill running on chronic stress-induced memory deficit in rats. J Bodyw Mov Ther 19 (2): 45-238.
[39] Renault, T. T., et al. 2014. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins. J Biol Chem 289 (38): 26481-91.
[40] Reza Zarrindast, M., et al. 2013. Effects of dopamine receptor agonist and antagonists on cholestasis-induced anxiolytic-like behaviors in rats. Eur J Pharmacol 702 (1-3): 25-31.
[41] Roma, M. G., F. A. Crocenzi, and E. A. Sanchez Pozzi. 2008. Hepatocellular transport in acquired cholestasis: new insights into functional, regulatory and therapeutic aspects. Clin Sci (Lond) 114 (9): 567-88.
[42] Ruiz-Gaspa, S., et al. 2014. Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis. Eur J Clin Invest 44 (12): 14-1206.
[43] Sari, S., et al. 2013. The Effect of Pentoxifylline on bcl-2 Gene Expression Changes in Hippocampus after Ischemia-Reperfusion in Wistar Rats by a Quatitative RT-PCR Method. Iran J Pharm Res 12 (3): 495-501.
[44] Savitskaya, M. A., and G. E. Onishchenko. 2015. Mechanisms of Apoptosis. Biochemistry (Mosc) 80 (11): 1393-405.
[45] Sedlak, T. W., and S. H. Snyder. 2004. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 113 (6): 1776-82.
[46] Serviddio, G., et al. 2014. Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis. Free Radic Biol Med 73: 117-26.
[47] Sheen, J. M., et al. 2010. Bile duct ligation in developing rats: temporal progression of liver, kidney, and brain damage. J Pediatr Surg 45 (8): 1650-8.
[48] Sokolovic, D., et al. 2010. Effect of L-arginine on metabolism of polyamines in rat's brain with extrahepatic cholestasis. Amino Acids 38 (1): 339-45.
[49] Swain, M. G. 2001. Cytokines and neuroendocrine dysregulation in obstructive cholestasis: pathophysiological implications. J Hepatol 35 (3): 416-8.
[50] Trauner, M., and J. L. Boyer. 2003. Cholestatic syndromes. Curr Opin Gastroenterol 19 (3): 216-31.
[51] Venketasubramanian, N., et al. 2015a. The NeuroAiD Safe Treatment (NeST) Registry: a protocol. BMJ Open 5 (11): e009866.
[52] Venketasubramanian, N., et al. 2015b. The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD). J Evid Based Med 8 (3): 149-53.
[53] Wolf, U., M. J. Rapoport, and T. A. Schweizer. 2009. Evaluating the affective component of the cerebellar cognitive affective syndrome. J Neuropsychiatry Clin Neurosci 21 (3): 245-53.
[54] Woolbright, B. L., et al. 2013. Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice. Toxicol Appl Pharmacol 273 (3): 524-31.
[55] Zarrindast, M. R., S. Hoseindoost, and M. Nasehi. 2012. Possible interaction between opioidergic and cholinergic systems of CA1 in cholestasis-induced amnesia in mice. Behav Brain Res 228 (1): 116-24.
